- Associated Press - Monday, July 23, 2012

DISAPPOINTING DATA: In the latest setback in Alzheimer’s research, an experimental drug failed the first of four late-stage studies. The treatment didn’t slow mental or functional decline in patients with mild or moderate Alzheimer’s who carry a gene that increases the risk of the disease.

WHAT’S NEXT: Development partners Pfizer Inc. and Johnson & Johnson will continue three other late-stage tests of bapineuzumab. Two studies are in patients who don’t have the ApoE4 gene.

WHAT’S AT STAKE: There’s no treatment that does more than temporarily ease Alzheimer’s symptoms, which afflict about 5 million Americans.

Copyright © 2018 The Washington Times, LLC.

The Washington Times Comment Policy

The Washington Times is switching its third-party commenting system from Disqus to Spot.IM. You will need to either create an account with Spot.im or if you wish to use your Disqus account look under the Conversation for the link "Have a Disqus Account?". Please read our Comment Policy before commenting.


Click to Read More and View Comments

Click to Hide